Genzyme launches MRD (minimal residual disease) test
This article was originally published in Clinica
Genzyme Genetics has launched a noninvasive test to detect minimal residual disease (MRD) in patients with B-cell chronic lymphocyte leukaemia (B-CLL). MRD refers to undetectable disease in the blood and bone marrow of leukaemia patients in complete remission.
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.